New IsoPSA assay detects prostate cancer more precisely than current tests

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease. Read the article here.

Video: “The Prostate Gland and Testosterone: relationship, importance to overall health, and the impact of prostate cancer and treatment on one’s health”

March 2017 Awareness Night The Prostate Gland and Testosterone: relationship, importance to overall health, and the impact of prostate cancer and treatment on one’s health Dr. Joseph R. LaBossiere, BMSc, MD, MSc, FRCSC Reconstructive Urology Fellow, Sunnybrook Health Sciences Centre             CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 58:43 minutes

Video: “The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment”

January 2017 Awareness Night The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment Dr. Raj Satkunasivam, MD, MS, FRCSC Urologic Oncologist,  Odette Cancer Centre, Sunnybrook Health Sciences Centre Assistant Professor, Division of Urology, Department of Surgery, University of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 40:51 minutes

Prostate Multiparametric MRI Feasible for PCa Screening

Robert K. Nam, MD, from the Sunnybrook Health Sciences Center in Toronto, and colleagues examined the feasibility of prostate MRI as the primary screening test for prostate cancer in a cohort of unselected men from the general population. All participants underwent prostate multiparametric MRI and random or targeted biopsies as well as prostate-specific antigen testing. Initial results showed that prostate MRI was better to predict prostate cancer than PSA. Read the article here.

New prostate cancer test strives to slash biopsies

Because PSA is secreted both by normal cells and cancer cells, its levels could be high for other reasons and not necessarily cancer: age, an inflammation of the prostate gland, or even a bicycle ride. But most often when doctors receive a high reading, they send their patients to do a biopsy, just to be on the safe side. Cleveland Diagnostics is developing a technology and test kit that can identify the PSA that specifically comes from cancer cells. Read the article here.

20th Anniversary Video

November 2014 Awareness Night – 20th Anniversary Celebration Watch this video of our 20th anniversary celebration: A bit of history from our founding as Man to Man to our joining the Prostate Cancer Canada Network Congratulatory messages from the medical community Our position on PSA testing as presented by PCC’s President and CEO Rocco Rossi   CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 54:38 minutes

Landmark PSA Screening Trial Results Challenged

Recommendations against routine PSA screening from the US Preventive Services Task Force (USPSTF) are based largely on a landmark trial showing that such screening does not decrease the risk of death from prostate cancer (PCa), but this conclusion may be invalid. Read the article.

Scroll to Top